Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties

Current Pharmaceutical Design

Volumn 9, Issue 28, 2003, Pages 2323-2335

  Avci, Fikri Y ^a   Karst, Nathalie A ^a   Linhardt, Robert J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Anticoagulant; Antithrombin III; Antithrombotic; Bis aldonic acid amides; Factor Xa; Heparin; Heparin pentasaccharide; PI 88; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APROSULATE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBOHYDRATE DERIVATIVE; FONDAPARINUX; GLUCONIC ACID; GLUCOSE DERIVATIVE; GLUCURONIC ACID; HEMATOLOGIC AGENT; HEPARIN; IDURONIC ACID; LACTOBIONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; LW 10114; LW 10121; LW 10125; LW 10168; LW 10244; MALTOHEPTAOSE; MALTOHEXAOSE; MALTOPENTAOSE; MALTOSE; MALTOTRIOSE; N (2 NAPHTHYLSULFONYL)GLYCYL 4 AMIDINOPHENYLALANINE PIPERIDIDE; OLIGOSACCHARIDE; PENTASACCHARIDE; PI 88; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICOAGULATION; BINDING AFFINITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; HEPARIN; HUMANS; MOLECULAR STRUCTURE; OLIGOSACCHARIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141886345     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453929     Document Type: Review

References (66)

1. Susanne A. Carbohydrates with anticoagulant and antithrombotic properties. In: Witczak, ZJ, Nieforth, KA, editors. Carbohydrates in drug design. New York: Marcel Dekker, INC. 1997,
2. Howell HW. The purification of heparin and its chemical and physiological reactions. Bull Johns Hopkins Hosp 1928; 42: 199,
3. Perlin AS, Mazurek M, Jaques LB. and Kavanaugh LW. A proton magnetic resonance spectral study of heparin. L-Iduronic acid residues in commercial heparins. Carbohydr Res 1968; 7: 369-379.
4. Lindahl U, Bäckström G, Thunberg L. and Leder IG, Evidence for a 3-O-sulfated D-Glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci 1980; 77: 6551-6555.
5. Atha DH, Lormeau J-C, Petitou M, Rosenberg RD. and Choay J. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochem 1985; 24: 6723-6729.
6. Linhardt RJ, Rice KG, Kim YS, Lohse DL, Wang HM. and Loganathan D. Mapping and quantification of the major oligosaccharide components of heparin. Biochem J 1988, 781: 781-787.
7. Linhardt RJ. Heparin: an important drug enters its seventh decade. Chem Indust 1991; 2: 45-50.
8. Lindahl U. Biosynthesis and related polysaccharides. In: Lane, DA, Lindahl U. editors. Heparin - chemical and biological properties, clinical applications. London: Edward Arnold; 1989; p. 159-189.
9. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
10. Beijering RJR, Cate H. and Cate JW. Clinical applications of new antithrombotic agents. Ann Hematol 1996; 72: 177-183.
11. van Boeckel CAA and Petitou M. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993; 32: 1671-1690.
12. van Boeckel CAA. Synthetic heparin-like antithrombotics. Pure & Appl Chem 1997; 69: 389-394.
13. Walenga JM, Jeske W, Bara L, Samama MM. and Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
14. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert J-M, van Boeckel CAA, et al. Fondaparinux, a synthetic pentasaccharide: The first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovascular Drug Reviews 2002; 20: 37-52.
15. Choay J, Lormeau J-C, Petitou M, Sinaÿ P. and Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Anti NY Acad Sci 1981; 370: 644-649.
16. Thumberg L, Bäckström G. and Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
17. Lindahl U, Bäckström G. and Thunberg L. The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group. J Biol Chem 1983; 258: 9826-9830.
18. Sinaÿ P, Jacquinet J-C, Petitou M, Duchaussoy P, Lederman I, Choay J, et al. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res 1984; 132: C5-C9.
19. van Boeckel CAA, Beetz T, Vos JN, De Jong AJM, van Aelst SF, van den Bosch RH, et al. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem 1985; 4: 293-321.
20. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinaÿ P, Jacquinet J-C, et al. Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(β-D-glucopyranosyluronic acid)-(1 → 4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res 1986; 147: 221-236.
21. Ichikawa Y, Monden R and Kuzuhara H. Synthesis of a heparin pentasaccharide fragment with a high affinity for antithrombin III employing cellobiose as a key starting material. Tetrahedron Lett 1986; 27: 611-614.
22. Petitou M, Duchaussoy P. and Lederman I. Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res 1987; 167: 67-75.
23. Meuleman DG, Hobbelen PMJ, van Dinther TG, vogel GMT, van Boeckel CAA. and Moelker HCT. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide. Semin Thromb Hemostasis 1991; 17: 112-117.
24. Lormeau J-C, Hérault J-P, Gaich C, Barzu T, van Dinther TG, Visser A, et al. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogs. Thromb Res 1997; 85: 67-75.
25. van Boeckel CAA, Beetz T and van Aelst SF. Synthesis of a potent antithrombin activating pentasaccharide. A new heparin-like fragment containing two-3-O-sulfated glucosamines. Tetrahedron Lett 1988; 29: 803-806.
26. Lucas H, Basten JEM, Van Dinther TG, Meuleman DG, van Aelst SF. and van Boeckel CAA. Syntheses of heparin-like pentamers containing opened uronic acid moieties. Tetrahedron 1990; 46: 8207-8228.
27. Perlin AS, Casu B, Sanderson GR and Johnson LF. 220 MHz spectra of heparin, chondroitins and other mucopolysaccharides. Can J Chem 1970; 48: 2260-2268.
28. Gatti G, Casu B. and Perlin AS. Conformations of the major residues in heparin. Proton NMR spectroscopic studies. Biochem Biophys Res Commun 1978; 85: 14-20.
29. Rees DA, Morris ER, Stoddart JF. and Stevens ES. Controversial glycosaminoglycan conformations. Nature 1985; 317: 480.
30. Torri G, Casu B, Gatti G, Petitou M, Choay J, Jacquinet J-C, et al. Mono- and bidimensional 500 MHz proton NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun 1985; 128: 134-140.
31. Ragazzi M, Ferro DR and Provasoli A. A force-field study of the conformational characteristics of the iduronate ring. J Comput Chem 1986; 7: 105-112.
32. Ferro DR, Provasoli A, Ragazzi M, Torri G, Casu B, Gatti G, et al. Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligo-saccharides: NMR and force-field studies. J Am Chem Soc 1986; 108: 6773-6778.
33. o conformer in the activation of antithrombin by heparin. Chem Eur J 2001; 7: 4821-4834.
34. Skinner R, Abrahams J-P, Whisstock J-C, Lesk AM, Carrell RW. and Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-609.
35. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN. and Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
36. Codée JDC, van der Marel GA, van Boeckel CAA. and van Boom JH. Probing the heparin-antithrombin III interaction using synthetic pentasaccharide bearing positively charged groups. Eur J Org Chem 2002; 2002: 3954-3965.
37. Lane DL, Denton J, Flynn A, Thunberg L. and Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 732-735.
38. Olson ST, Halvorson HR. and Björk I. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem 1991; 266: 6342-6352.
39. Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost 1997; 78: 1422-1425.
40. Grootenhuis PDJ, Westerduin P, Meuleman DG, Petitou M. and van Boeckel CAA. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity. Nature Struct Biol 1995; 2: 736-739.
41. Petitou M, Imberty A, Duchaussoy P, Driguez P-A, Ceccato ML, Gourvenec F, et al. Experimental proof for the structure of a thrombin-inhibitig heparin molecule. Chem Eur J 2001; 7: 859-873.
42. Petitou M, Duchaussoy P, Driguez P-A, Jaurand G, Hérault J-P, Lormeau J-C, et al. First Synthetic carbohydrates with the full anticoagulant properties of heparin. Angew Chem Int Ed Engl 1998; 37: 3009-3014.
43. Petitou M, Duchaussoy P, Driguez P-A, Hérault J-P, Lormeau J-C. and Herbert J-M. New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Bioorg Med Chem Lett 1999; 9: 1155-1160.
44. Petitou M, Driguez P-A, Duchaussoy P, Hérault J-P, Lormeau J-C. and Herbert J-M. Synthetic oligosaccharides having various functional domains: Potent and potentially safe heparin mimetics. Bioorg Med Chem Lett 1999; 9: 1161-1166.
45. Petitou M, Hérault J-P, Bernat A, Driguez P-A, Duchaussoy P, Lormeau J-C, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-422.
46. Driguez P-A, Lederman I, Strassel J-M, Herbert J-M. and Petitou M. Synthetic carbohydrate derivatives as low sulfated heparin mimetics. J Org Chem 1999; 64: 9512-9520.
47. Buijsman RC, Basten JEM, van Dinther TG, van der Marel GA, van Boeckel CAA. and van Boom JH. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg Med Chem Lett 1999; 9: 2013-2018.
48. Parolis LA, Parolis H, Kenne L, Meldal M. and Bock K. The extracellular polysaccharide of Pichia (Hansenula) holstii NRRL Y-2448: the phosphorylated side chains. Carbohydr Res 1998; 309 77-87.
49. Ferro V, Fewings K, Palermo MC. and Li C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of P1-88. Carbohydr Res 2001; 332: 183-189.
50. Yu G, Gunay NS, Linhardt RJ, Toida T, Fareed J, Hoppensteadt DA, et al. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur J Med Chem 2002; 37: 783-791.
51. Parish CR, Freeman C, Brown KJ, Francis DJ and Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-3441.
52. McGarry M. The effect of the heparanase inhibitor PI-88 on neo-intimal formation following acute arterial injury. Brisbane: University of Quinsland; 1999.
53. Wall D, Douglas S, Ferro V, Cowden W. and Parish C. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb Res 2001; 103: 325-335.
54. Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, et al. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thrombosis/Hemostasis 2001; 7: 131-140.
55. Isbell HS. and Frush HL. Lactonization of aldonic acids. In: Whistler, RL, Wolfram, ML,Bemiller, JN, editors. Methods in Carbohydrate Chemistry. New York: Academic Press, 1963. p. 16-18.
56. Sugidachi A, Asai F. and Koike H. In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity. Thromb Res 1993; 69: 71-80.
57. Ofosu FA, Fareed J, Smith LM, Anvari N, Hoppensteadt DA and Blajchman MA. Inhibition of factor X, factor V. and prothrombin activation by the bis (lactobionic acid amide) LW 10082. Eur J Biochem 1992, 203: 121-125.
58. Hoppensteadt DA, Ahsan A, Walenga J-M, Fareed J. and Schumacher H. Activation of heparin cofactor II by sulfated lactobionic acid. Blood 1988, 72: 198a.
59. Papoulias UE, Wyld PJ, Haas S, Stemberger A, Jeske W, Hoppensteadt DA, et al. Phase-1 study with aprosulate, a new synthetic anticoagulant. Thromb Res 1993; 72: 99-108.
60. Raake W, Klauser RJ. and Meinetsberger E. Antithrombotic activities of aprosulate sodium (LW 10082) and its neutralisation by protamine. Semin Thromb Hemostasis 1993; 19: 183-185.
61. Sugidachi A, Breiter N, Ogawa T, Asai F. and Koike H. In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: Possible mechanism for antiplatelet action. Thromb Haemost 1996; 76: 786-790.
62. Raake W, Klauser RJ, Elling H, Zeiller P. and Meinetsberger E. Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties. Semin Thromb Hemostasis 1994; 20: 176-181.
63. Martin DJ, Toce JA, Anevski PJ, Tollefsen DM. and Abendschein DR. Anticoagulant and antithrombotic activitiy of maltodapoh, a novel sulfated tetrasaccharide. J Pharmacol Exp Ther 1998; 288: 516-521.
64. Gryglewski RJ, Marcinkiewicz E, Robak J, Michalska Z, Madej J. Mesoionic oxatriazoles (MOTA): NO-donating characteristics and pharmacology. Curr Pharm Design 2002; 8(3): 167-76.
65. MacDonald KP, Hill GR. Keratinocyte Growth Factor (KGF) in hematology and oncology. Curr Pharm Design 2002; 8(5): 395-403.
66. Salzet M. Leech thrombin inhibitors. Curr Pharm Design 2002; 8(7): 493-503.